Differential effects of BCG-Russia and BCG-TICE on trained immunity: Potential implications for bladder cancer immunotherapy
Richard W Nauman, Peter A Greer, Andrew W Craig, Tiziana Cotechini, D Robert Siemens, Charles H Graham · 2026
Read Differential effects of BCG-Russia and BCG-TICE on trained immunity: Potential implications for bladder cancer immunotherapy by Richard W Nauman, Peter A Greer, Andrew W Craig, Tiziana Cotechini, D Robert Siemens, Charles H Graham (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0357950.txt.
Description
Richard W. Nauman and colleagues published a 2026 immunology study in PLOS ONE comparing two strains of BCG, the vaccine bacteria also used as a bladder cancer treatment. North American treatment has relied on one strain, but supply problems have pushed interest in an alternative strain produced in Russia. Because much of BCG's benefit is thought to come from trained immunity, a lasting priming of the innate immune system. The team gave mice one dose of each strain and examined bone marrow weeks later.
Both strains expanded the blood-forming stem cells that seed immune responses. The long-used strain, however, produced stronger trained immunity, with immune cells releasing more inflammatory signals when challenged again, and it switched on more inflammation-related genes. The Russian strain primed the system more weakly. Such strain differences, the authors say, could matter for how well bladder cancer immunotherapy works if supplies force a switch.
Catalog record
| CREATOR | Richard W Nauman, Peter A Greer, Andrew W Craig, Tiziana Cotechini, D Robert Siemens, Charles H Graham |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37347 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |